COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00160212
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : January 30, 2009
Information provided by:
Solvay Pharmaceuticals

Brief Summary:
This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Daglutril Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension
Study Start Date : December 2004

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • sitting office diastolic blood pressure between 90 and 109 mmHg
  • office systolic blood pressure between 140 and 179 mmHg
  • mean day-time diastolic 24-h ABPM blood pressure >= 85 mmHg inclusive at baseline

Exclusion Criteria:

  • known secondary hypertension
  • decompensated congestive heart failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00160212

Show Show 130 study locations
Sponsors and Collaborators
Solvay Pharmaceuticals
Layout table for investigator information
Study Director: Global Clinical Director Solvay Solvay Pharmaceuticals
Layout table for additonal information Identifier: NCT00160212    
Other Study ID Numbers: S306.2.008
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: January 30, 2009
Last Verified: January 2009
Keywords provided by Solvay Pharmaceuticals:
blood pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases